Danaher Corporation $DHR Stock: Robertson Stephens Wealth Management LLC Increases Stake

Robertson Stephens Wealth Management LLC increased its holdings in Danaher Corporation (NYSE:DHR) by 44.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,199 shares of the conglomerate’s stock after acquiring an additional 6,259 shares during the quarter. Robertson Stephens Wealth Management LLC’s holdings in Danaher were worth $4,475,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in DHR. BlackRock Inc. bought a new position in Danaher in the 2nd quarter worth $10,492,520,000. Jupiter Topco LLC bought a new stake in shares of Danaher during the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP bought a new stake in shares of Danaher during the 2nd quarter valued at about $1,287,949,000. Bank of America Corp DE bought a new stake in shares of Danaher during the 2nd quarter valued at about $993,846,000. Finally, Legal & General Group Plc purchased a new position in shares of Danaher during the second quarter valued at about $801,056,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR opened at $228.87 on Friday. The stock has a fifty day simple moving average of $214.04 and a two-hundred day simple moving average of $195.97. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market cap of $160.89 billion, a price-to-earnings ratio of 40.65, a price-to-earnings-growth ratio of 2.88 and a beta of 0.76. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the firm posted $0.77 earnings per share. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. Research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is 28.42%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DHR. Evercore reiterated an “outperform” rating and set a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. The Goldman Sachs Group raised their price objective on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Morgan Stanley lifted their price objective on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Finally, Barclays upped their target price on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.